Alpha 2.0
Login Register
» Authors » Andrea Antinori

Andrea Antinori

Explore the profile of Andrea Antinori including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 518
Citations 8963
Followers 0
Related Specialties
Infectious Diseases
Microbiology
General Medicine
Top 10 Co-Authors
Antonella dArminio Monforte
Enrico Girardi
Cristina Mussini
Carlo Federico Perno
Alessandro Cozzi-Lepri
Carmela Pinnetti
Emanuele Nicastri
Valentina Mazzotta
Alessandra Vergori
Andrea De Luca
Published In
J Acquir Immune Defic Syndr
AIDS
Antivir Ther
J Int AIDS Soc
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation
Gagliardini R, Giacomelli A, Mussini C, Cole S, Edwards J, Pinnetti C, et al.
Int J Infect Dis . 2025 Mar; :107883. PMID: 40089053
Background: No randomized comparisons exist between dolutegravir (DTG) and boosted-darunavir (DRV/b) for people initiating treatment with advanced HIV. Methods: ART-naïve people with HIV (PWH) with CD4 <200 cells/mm or AIDS...
2.
Assessing Torquetenovirus (TTV) as a Biomarker for Immune Responses to SARS-CoV-2 mRNA Vaccines in People Living with HIV and Healthy Individuals
Minosse C, Spezia P, Mazzotta V, Matusali G, Meschi S, Colavita F, et al.
Vaccines (Basel) . 2025 Feb; 13(2). PMID: 40006700
: Torquetenovirus (TTV) viremia is increasingly recognized as a marker of immune competence. In the context of COVID-19, TTV viral load (VL) has been shown to predict anti-Spike antibody levels...
3.
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort
Taramasso L, Rossotti R, Tavelli A, Santoro M, Mazzotta V, Bandera A, et al.
J Acquir Immune Defic Syndr . 2025 Feb; 98(4):352-356. PMID: 39970315
Background: The best therapeutic management for people with HIV (PWH) who have a history of preexposure prophylaxis (PrEP) is still debated. Objectives: The aim of this study was to describe...
4.
ORCHESTRA Delphi Consensus: Diagnostic and Therapeutic Management of SARS-CoV-2 Infection in Solid Organ Transplant Recipients
Tazza B, Caroccia N, Toschi A, Pascale R, Gkrania-Klotsas E, Navarro P, et al.
Clin Microbiol Infect . 2025 Feb; PMID: 39954948
Objectives: Our aim was to address existing knowledge gaps regarding risk stratification, best use of diagnostic resources, optimal treatment and general management of SARS-CoV-2 infection in solid organ transplant (SOT)...
5.
Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
Mazzotta V, Piselli P, Lepri A, Matusali G, Cimini E, Esvan R, et al.
Vaccines (Basel) . 2025 Jan; 13(1). PMID: 39852811
Background: The recent resurgence of mpox in central Africa has been declared a new public health emergency of international concern (PHEIC) requiring coordinated international responses. Vaccination is a priority to...
6.
Innate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients
Casetti R, Sacchi A, Mazzotta V, Cristofanelli F, Grassi G, Gili S, et al.
Int Immunopharmacol . 2025 Jan; 148:113934. PMID: 39832460
The impact of anti-Spike monoclonal antibody (mAbs) treatment on the immune response of COVID19-patients is poorly explored. In particular, a comparison of the immunological influence of different therapeutic regimens has...
7.
Vδ2 T-cells response in people with Mpox infection: a three-month longitudinal assessment
Cimini E, Tartaglia E, Messina F, Coppola A, Mazzotta V, Tempestilli M, et al.
Emerg Microbes Infect . 2025 Jan; 14(1):2455585. PMID: 39817429
The first evidence that Orthopoxvirus induced the expansion and the recall of effector innate Vδ2 T-cells was described in a macaque model. Although, an engagement of αβ T-cells specific response...
8.
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort
Antinori A, Marchetti G, Esposito V, Rusconi S, Canetti D, Quiros-Roldan E, et al.
Int J STD AIDS . 2025 Jan; 36(4):309-318. PMID: 39772928
Background: BICSTaR is a multi-national, observational cohort evaluating the effectiveness, safety, and patient-reported outcomes (PROs) in treatment-naïve (TN) and -experienced (TE) people with HIV-1 receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine...
9.
Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic
Vergori A, Gianotti N, Tavelli A, Tincati C, Giacomelli A, Matteini E, et al.
Viruses . 2025 Jan; 16(12. PMID: 39772133
: This study examined the impact of the COVID-19 lockdown on antiretroviral therapy (ART) prescriptions among persons living with HIV (PWH) in Italy. : Data from the ICONA cohort included...
10.
Effectiveness and Tolerability of DOR/3TC/TDF in Experienced People with HIV Switching from RPV/FTC/TDF: A Retrospective, Single Center Cohort Study
Cicalini S, Lanini S, Gagliardini R, Bellagamba R, Vergori A, Mastrorosa I, et al.
Pharmaceuticals (Basel) . 2025 Jan; 17(12. PMID: 39770548
With advances in antiretroviral therapy for HIV treatment, newer drug combinations provide improved efficacy, safety, and compliance. This study evaluates switching to a regimen of doravirine (DOR), tenofovir disoproxil fumarate...